In collaboration with RadioMedix, a US-based radiopharmaceutical company, the company is co-developing a theranostic agent for an especially aggressive form of brain cancer, glioblastoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback